Brilacidin-ABSSSI will be a Phase 3 clinical trial when the company has the estimated $30 million it will cost to complete such a trial.
So yes, Brilacidin is fairly characterized as a drug awaiting a Phase 3 clinical trial.
(1)
(0)
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
-
-
-
-
-
-
-